The MOU sets out the basis for KGK to commence research and development of a GLP1 supplement for use in companion animals. Combining a GLP1 supplement with Better Choices’ Halo branded toppers or treats for dogs and cats to treat obesity and other health issues associated with overweight pets is an area of growing interest as more than half of dogs and cats worldwide are classified as overweight or obese.
KGK is a leading Canadian researcher organization that provides high-quality clinical research trials and expert regulatory support to several industries. For over 25 years, KGK has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products efficiently into global markets. KGK is one of the most reliable resources for brands looking for an experienced, trustworthy team of scientific researchers, consultants, and regulatory specialists to develop customized claim substantiation and path-to-market strategies.
“We are pleased to make progress with our R&D partners APH and KGK. We see the use of the GLP1 supplement as a significant opportunity for the pet health industry and are assembling top tier partners to help
About
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. The Company has based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Some or all of the results anticipated by these forward-looking statements may not be achieved. Further information on the Company’s risk factors is contained in our filings with the
Company Contact:
Investor Contact:
T: 212-896-1254
Valter@KCSA.com
Source:
2023 GlobeNewswire, Inc., source